Axiron/androgel sales over last quarter.

  1. 8,081 Posts.
    lightbulb Created with Sketch. 675
    Comparing to previous quarter (Q4 is always Seasonally strong and Q1 is always weak), Axiron dropped 17%, but Androgel dropped sharp 40%.
    With both main products are facing competition from generic drugs, it seems Axiron may maintain or even increases the market share but Androgel lost a lots.

    The figure will show Axiron' market share likely above 14% at the worst.

    $39.1m is not a rally, but further convinced sales stabilizing and FDA' impact is fading.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.5¢
Change
0.000(0.00%)
Mkt cap ! $5.934M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
5 2720106 1.4¢
 

Sellers (Offers)

Price($) Vol. No.
1.5¢ 866911 4
View Market Depth
Last trade - 16.21pm 12/09/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.